BTIG analyst Thomas Shrader has maintained their bullish stance on GANX stock, giving a Buy rating on November 13.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Thomas Shrader’s rating is based on several promising developments in Gain Therapeutics’ clinical trials and financial health. The company’s investigational drug, GT-02287, has shown potential in treating Parkinson’s disease by improving key clinical scores and demonstrating a disease-slowing effect. The drug was well tolerated with no significant adverse events, and a majority of participants opted to continue treatment, indicating positive patient reception.
Furthermore, the upcoming biomarker data is anticipated to provide further insights into the drug’s efficacy, particularly in clearing harmful deposits in lysosomes, which could be a significant breakthrough. Financially, the company maintains a stable cash position, and the valuation using a discounted cash flow analysis suggests potential growth. These factors combined contribute to Shrader’s Buy rating for Gain Therapeutics.
In another report released on November 13, Roth MKM also reiterated a Buy rating on the stock with a $6.00 price target.